But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

Expert Rev Gastroenterol Hepatol. 2012;6(1):105-114. When double-stent placement (duodenal and biliary) is considered, biliary stent placement can be performed either preceding or following ...

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s ...